HedgePath Pharmaceuticals, Inc. – ‘NTN 10Q’ for 9/30/97

As of:  Tuesday, 12/2/97   ·   For:  9/30/97   ·   Accession #:  916641-97-1143   ·   File #:  1-13467

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Notice of a Late Filing of a Form 10-Q (Late Notice)   —   Rule 12b-25
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: NTN 10Q     Commonwealth Biotechnologies, Inc Nt 10-Q              4     12K 

NTN 10Q
1st Page of 4
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
U.S. SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

FORM 12b-25 

NOTIFICATION OF LATE FILING                                                     

                                                                 SEC FILE NUMBER
                                                                 001-13467

                                                                  CUSIP NUMBER
                                                                 202739 10 8

Form 10-K and Form                                 Form 10-Q and Form           
  10-KSB [ ]    Form 20-F [ ]     Form 11-K [ ]    10-QSB [X]    Form N-SAR  [ ]

For Period Ended:  September 30, 1997                                           

[ ]     Transition Report on Form 10-K                                          
[ ]     Transition Report on Form 20-F                                          
[ ]     Transition Report on Form 11-K                                          
[ ]     Transition Report on Form 10-Q                                          
[ ]     Transition Report on Form N-SAR                                         

For the Transition Period Ended:                                                

Nothing in this form shall be construed to imply that the Commission has        
verified any information contained herein.                                      

If the notification relates to a portion of the filing checked above, identify  
the Item(s) to which the notification relates:                                  

NTN 10Q
2nd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 2nd
PART I - Registrant Information                                                 

Full Name of Registrant:   Commonwealth Biotechnologies, Inc.                   

Former Name, if Applicable:         N/A                                         

Address of Principal Executive Office:       911 East Leigh Street, Suite G-19, 
                                  Richmond, Virginia 23219

PART II - Rules 12b-25(b) and (c)                                               

If the subject report could not be filed without unreasonable effort or expense 
and the registrant seeks relief pursuant to Rule 12b-25, the following should be
completed (check box if appropriate):                                           

(a)      The reasons described in reasonable detail in Part III of this form    
      could not be eliminated without unreasonable effort or expense.  [X]

(b)      The subject annual report, semi-annual report, transition report on    
     Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or a portion thereof
     will be filed on or before the fifteenth calendar day following the
    prescribed due date; or the subject quarterly report or transition
        report on Form 10-Q or Form 10-QSB, or a portion thereof will be filed
        on or before the fifth calendar day following the prescribed due date.
[X]                                                           

(c)      The accountant's statement or other exhibit required by Rule 12b-25(c) 
has been attached if applicable.  [ ]                         

PART III - Narrative                                                            

State below in reasonable detail the reasons why Form 10-K and Form 10-KSB,     
20-F, 11-K, 10-Q and Form 10-QSB, N-SAR, or the transition report or portion    
thereof could not be filed within the prescribed period:                        

        The Company is currently seeking clarification from the Securities and
Exchange Commission regarding the interaction of relevant Staff Accounting      
Bulletins (Topic 4D) for initial public offerings and FASB Statement 128,       
Earnings Per Share. FASB Statement 128 will require retroactive computations of 
earnings per share in 1998 for the period ended September 30, 1997. As Topic 4D 
specifies that anti-dilutive securities be given effect in the earnings per     
share calculations, including filings subsequent to the Company's initial public
offering that include the period the initial public offering became effective,  
and FASB 128 requires a retroactive computation that would not give effect to   
the anti-dilutive securities, the Company is seeking clarification from the     
Office of Small Business on this issue. The Office of Small Business has        
indicated that they will respond by Tuesday, December 2, 1997. The Company      
anticipates filing the Form 10-QSB for the period ended September 30, 1997      
shortly thereafter.                                                             

NTN 10Q
3rd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 3rd
        The Company is not filing other parts of the Form 10-QSB at this time,
as it believes that the effect of the anti-dilutive securities is material and  
relevant to the financial statements and management's discussion and analysis   
taken as a whole. In addition, such information would be potentially misleading 
to investors without the appropriate disclosures required for recent accounting 
pronouncements.                                                                 

PART IV - Other Information                                                     

(1)      Name and telephone number of person to contact in regard to this       
notification: J. Benjamin English, Esq.  (804) 783-2003       

(2)      Have all other periodic reports required under Section 13 or 15(d) of  
     the Securities Exchange Act of 1934 or Section 30 of the Investment
        Company Act of 1940 during the preceding 12 months or for such shorter
     period that the registrant was required to file such report(s) been
filed? If the answer is no, identify report(s). [X] Yes [ ] No

(3)      Is it anticipated that any significant change in the results of        
        operations from the corresponding period for the last fiscal year will
       be reflected by the earnings statements to be included in the subject
report or portion thereof? [ ] Yes [X] No                     

If so, attach an explanation of the anticipated change, both  
narratively and quantitatively, and, if appropriate, state the reasons why a    
reasonable estimate of the results cannot be made.                              

NTN 10Q
Last Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 4th
       Commonwealth Biotechnologies, Inc. has caused this notification to be
signed on its behalf by the undersigned thereunto duly authorized.              

                          COMMONWEALTH BIOTECHNOLOGIES, INC.

                  By:  /s/  Robert B. Harris
                      ------------------------
                             Robert B. Harris,
                     President

Date:    December 2, 1997                                                       

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘NTN 10Q’ Filing		Date		First		Last			Other Filings
Filed on:		12/2/97		2		4
For Period End:		9/30/97		1		2			10QSB,  10QSB/A
									List all Filings